COMPARATIVE STUDY OF EFFECTIVENESS AND RESISTANCE PROFILE OF CHLOROQUINE AND SULFADOXINE-PYRIMETHAMINE IN UNCOMPlicated PLASMODIUM FALCIPARUM MALARIA IN KOLKATA

Ayan Basu1, Santanu Saha2, Biswanath Sharma Sarkar3, Somnath Mukherjee4, Subhasish Kamal Guha5, Dyuti Basu6

ABSTRACT: Malaria is one of the major public health problems of the country. Factors responsible for re-emergence of malaria in India was due to emergence and spread of chloroquine resistant Plasmodium falciparum strains across the country coupled with steady rise in insecticide resistance of the vector mosquitoes. Very little is known about the drug resistance status of P. falciparum in India. As per National Vector Borne Diseases Control Programme (NVBDCP), chloroquine is the drug of choice for uncomplicated P. falciparum cases and the combination of Artesunate and Sulfadoxine-Pyrimethamine(SP) is being used to treat the documented chloroquine resistant uncomplicated cases. To evaluate the comparative effectiveness and resistance profile of Chloroquine vis-à-vis Sulfadoxine-Pyrimethamine (SP) in uncomplicated Plasmodium falciparum cases as the first line therapy a study was undertaken at the Malaria Clinic of School of Tropical Medicine, Kolkata during the period from July 2008 to January 2009 under Ward no. 44 of Kolkata Municipal Corporation. Following WHO protocol 2003 and WHO guideline 2006, a total of 100 parasitologically confirmed Plasmodium falciparum cases were recruited as per the recruitment criteria. Among them, 50 patients were given Chloroquine and another 50 patients were given SP. Eight patients were excluded or lost to follow-up during the follow-up period because of failure to follow the protocol. It was observed that in the chloroquine group out of 50 patients, 30 (60%) showed Adequate Clinical and Parasitological Response (ACPR), 15 (30%) had Late Treatment Failure (LTF) and remaining 5 (10%) were lost during the follow up period (LFU). On the other hand in the SP group out of 50 patients, 46 (92%) showed ACPR and only one (2%) had LTF and 3 patients were LFU. The difference of LTF in Chloroquine and Sulfadoxine-pyrimethamine groups was statistically significant (p value < 0.05). Also there was statistically significant difference of the mean Parasite clearance time (PCT) of Chloroquine (82.7 hours) and Sulfadoxine-pyrimethamine group (61.3 hours). Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (>10%). Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P. falciparum cases.

KEY WORDS: Plasmodium falciparum, Chloroquine, Sulfadoxine- Pyrimethamine, efficacy and drug resistance.

INTRODUCTION: Malaria is the most important of the parasitic diseases of humans, with transmission in 107 countries containing 3 billion people, infecting approximately 5% of the world’s population and causing 1-3 million deaths each year. Malaria is one of the major public health problems of the country. Around 1.5 million laboratory confirmed cases of malaria are reported in
the country annually. Out of the total malaria cases, 40-50% is Plasmodium falciparum. About 1.785 million cases of malaria (including 0.839 million P. falciparum cases) and 1708 deaths were reported from the country in 2006. Recently 1.525 million cases of malaria (including 0.756 million Plasmodium falciparum cases) and 935 deaths were reported in 2008 (Provisional data given by NVBDCP in Feb 2009).¹

Major factors responsible for re-emergence of malaria in India was due to emergence and spread of chloroquine resistant Plasmodium falciparum strains across the country coupled with steady rise in insecticide resistance of the vector mosquitoes. The first evidence of chloroquine (CQ) resistant P. falciparum was noted in India in 1973 from Dipu area of Karbi Anglong district of Assam. Several reports of resistance were subsequently confirmed from Arunachal Pradesh, Andhra Pradesh, Assam, Chhatisgarh, Goa, Gujarat, Jharkhand, Madhya Pradesh, Maharashtra, Meghalaya, Mizoram, Nagaland, Orissa, Rajasthan, Tripura, Uttar Pradesh, Karnataka, West Bengal, and Andaman Nicobar Islands. In West Bengal, during 1982-1988, Pandeya et al. (1991)² reported one R-III focus in Purulia and two R-III foci in the district of Jalpaiguri. In recent years multi-drug resistant P. falciparum malaria has also been reported from various countries. Very little is known about the drug resistance status of P. falciparum in India. As per National Vector Borne Diseases Control Programme (NVBDCP), chloroquine is the drug of choice for uncomplicated P. falciparum cases and the combination of Artesunate and sulfadoxine-pyrimethamine is being used to treat the documented chloroquine resistant uncomplicated cases. There has been a steady rise in the proportion of recurrent P. falciparum cases (following use of recommended doses of chloroquine) attending the Malaria Clinic of School of Tropical Medicine, Kolkata (32.7% in 2001 and 66.5% in 2005). A significant proportion of recurrent P. falciparum cases are due to chloroquine resistance (Biswas S., 2003)³. With continued use of chloroquine as first line of therapy, the number of people with RI resistance and consequently the parasite burden in the community are also increasing. This results in increased transmission of P. falciparum in the community. Recently deaths due to P. falciparum malaria have been recorded in Kolkata, foothills of Purulia and certain Tea Estates of Dooars area of Jalpaiguri (Government data). While chloroquine remains the first line drug for uncomplicated P. falciparum malaria as per NVBDCP, a section of doctors, in private as well as in Government sector, are using the Artemisinin derivatives and Quinine indiscriminately to treat uncomplicated P. falciparum malaria cases. Injudicious use of such reserved anti-malarial drugs might lead to development of rapid resistance against them. In endemic areas it’s difficult to differentiate “recrudescence” and “re-infection” clinically and/or parasitologically.

This prompted us to undertake a pilot study to evaluate the effectiveness and resistance profile of chloroquine vis-à-vis sulfadoxine-pyrimethamine in uncomplicated Plasmodium falciparum cases as the first line therapy.

PATIENTS AND METHODS:

Study sites: The present study was undertaken at the Malaria Clinic of Calcutta School of Tropical Medicine, Kolkata during the period from July 2008 to January 2009 under Ward no. 44 of Kolkata Municipal Corporation, Kolkata.

Patients: A total of 100 patients were enrolled in this study (50 patients each in Chloroquine and Sulfadoxine pyrimethamine group). The patients of confirmed Plasmodium falciparum malaria from
Malaria Clinic were randomly screened and finally recruited for the study using following inclusion and exclusion criteria.

**Inclusion criteria**
- a. Patients belonging to ward no. 44, Kolkata Municipal Corporation
- b. Of either sex and above the age of six months
- c. Microscopically proved cases of *Plasmodium falciparum* (monoinfection)
- d. Parasite density between 1,000-100,000/µL of blood.
- e. Axillary temperature of ≥ 37.5 °C or history of fever in previous 24 hours
- f. Ability to follow up visits and easy access to health facilities
- g. Informed consent of the patient/parent/guardian

**Exclusion criteria**
- a. History of taking antimalarials within 15 days preceding the illness
- b. Presence of mixed infection
- c. Inability to provide informed consent
- d. Appearance of any of the criteria of severe or complicated malaria during the present illness
- e. Pregnancy and history of amenorrhea
- f. Patients with sulfonamide hypersensitivity and known G6PD deficiency

**Treatment & follow up:** Study design was done as per WHO protocol 2003 and WHO guideline 2006. This protocol consists of recording essential patient information, clinical assessment, axillary temperature, parasitemia, bodyweight on day 0 (prior to treatment) and with the stipulated drug, clinical assessment with examination of axillary temperature on Days 1, 2, 3, 7, 14, 21 & 28 and parasitological examination on Days 2, 3, 7, 14, 21 & 28. On Day 1 or any other day the patient was also examined for parasitemia, if he/she had any danger sign or clinical deterioration. Both thick and thin smears were taken in the same slide from finger pricked blood sample, were stained with Giemsa stain and examined under oil immersion lens microscope on Day 0, 2, 3, 7, 14, 21, 28 and on any unscheduled day.

(Figure: Thick & thin blood smear showing Giemsa stained *Plasmodium falciparum* ring under oil immersion with 100X magnification)
Parasite load was measured by counting number of asexual forms of Plasmodium falciparum parasites against 200 leucocytes present in stained thick blood smear. In case of low parasitemia (less than 10/200 leucocytes), counting was done against 500 leucocytes. The parasite load was calculated by applying the following formula.

\[
\text{Parasitemia (per micro-litre)} = \frac{\text{Number of parasites} \times 8000}{\text{Number of leukocytes}}
\]

As per National Drug Policy on Malaria (2008) by National Vector Borne Disease Control Programme (NVBDCP) the following dosage schedule was used:

<table>
<thead>
<tr>
<th>Age in years</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chloroquine Tablet (150 mg base)</td>
<td>Primaquine (Base in mg)</td>
<td>No. of tablets (7.5mg)</td>
</tr>
<tr>
<td>&lt; 1</td>
<td>½</td>
<td>NIL</td>
<td>0</td>
</tr>
<tr>
<td>1 - 4</td>
<td>1</td>
<td>7.5</td>
<td>1</td>
</tr>
<tr>
<td>5 - 8</td>
<td>2</td>
<td>15</td>
<td>2</td>
</tr>
<tr>
<td>9 - 14</td>
<td>3</td>
<td>30</td>
<td>4</td>
</tr>
<tr>
<td>≥ 15</td>
<td>4</td>
<td>45</td>
<td>6</td>
</tr>
</tbody>
</table>

Table A: Dosage schedule of Chloroquine + Primaquine

<table>
<thead>
<tr>
<th>Age in years</th>
<th>Sulfadoxine + Pyrimethamine (on Day 1)</th>
<th>Primaquine (on Day 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sulfadoxine (mg base)</td>
<td>Pyrimethamine (mg base)</td>
</tr>
<tr>
<td>&lt; 1</td>
<td>125</td>
<td>6.25</td>
</tr>
<tr>
<td>1 - 4</td>
<td>500</td>
<td>25</td>
</tr>
<tr>
<td>5 - 8</td>
<td>750</td>
<td>37.5</td>
</tr>
<tr>
<td>9 – 14</td>
<td>1000</td>
<td>50</td>
</tr>
<tr>
<td>≥ 15</td>
<td>1500</td>
<td>75</td>
</tr>
</tbody>
</table>

Table B: Dosage schedule of Sulfadoxine-Pyrimethamine + Primaquine

Classification of therapeutic response according to WHO Protocol 2003 and WHO guideline 2006

There are three categories of therapeutic responses, namely 'Early Treatment Failure' (ETF), 'Late Treatment Failure' (LTF) and 'Adequate Clinical and Parasitological Response (ACPR)’. These are defined as follows:

- Early Treatment Failure (ETF) if the patient develops one of the four conditions during the first three days of follow up.
  - Development of danger signs or severe malaria on Day 1, Day 2 or Day 3, in the presence of parasitemia
  - Parasitemia on Day 2 higher than Day 0 count irrespective of axillary temperature
Parasitemia on Day 3 with axillary temperature ≥ 37.5 degree centigrade
Parasitemia on Day 3 greater than or equal to 25% of the count on Day 0

Late Treatment Failure (LTF) is of 2 types:
1) Late Clinical Failure (LCF)
   - Development of danger signs or severe malaria after Day 3 in presence of parasitemia, without previously meeting any criteria of Early Treatment Failure
   - Presence of parasitaemia and axillary temperature ≥ 37.5 °C on any day from Day 4 to Day 28, without previously meeting any of the criteria of Early Treatment Failure

2) Late Parasitological Failure (LPF)
   Presence of parasitaemia on any day from Day 7 to Day 28 and axillary temperature < 37.5 °C, without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure

Adequate Clinical and Parasitological Response (ACPR)
Absence of parasitaemia on Day 28 irrespective of axillary temperature without previously meeting any of the criteria of Early Treatment Failure or Late Clinical Failure or Late Parasitological Failure

Fever Clearance Time (FCT)
This is the time from beginning of antimalarial treatment until the patient isapyrexial. This is of two types - FCTa and FCTb. FCTa is when temperature first falls below 37.5 °C (i.e. 99.5 °F) and FCTb is when the temperature falls and remains below 37.5 °C for 24 hours. In this study FCTa has consistently been taken into consideration.

Parasite Clearance Time (PCT)
It is the time between beginning the anti-malarial treatment and the first negative blood slide.

RESULTS: In the present study a total of 100 parasitologically confirmed Plasmodium falciparum cases belonging to ward no 44 under Kolkata Municipal Corporation were recruited during the period from July 2008 to January 2009 as per the recruitment criteria. Among them, 50 patients were given chloroquine and another 50 patients were given sulfadoxine-pyrimethamine. Eight patients were excluded or lost to follow-up (five patients in the chloroquine arm and 3 patients in the sulfadoxine-pyrimethamine arm) during the follow-up period because of failure to follow the protocol (antimalarial treatment administered by themselves or a third party) or failure to come for follow-up on the scheduled days.

There were 87 male patients (87%) and 13 female patients (13%). In the chloroquine arm there were 42 (84%) male patients and 8 (16%) female patients and in the sulfadoxine-pyrimethamine arm there were 45 male patients (90%) and 5 (10%) female patients.

The mean age at presentation was 32.4 years (Range 10-62, Median 30). For chloroquine arm the mean age was 33.3 years (Range 10-62, Median 32.5) and for sulfadoxine-pyrimethamine arm the mean age was 31.5 years (Range 13-62, Median 29.5).
According to the study protocol, Plasmodium falciparum parasitemic patients with fever of >37.5°C (or >99.5°F) or with history of fever within the previous 24 hrs. were enrolled. On Day 0, the mean temperature in the Chloroquine group was 100.56°F (range 96-103.6°F) and that of Sulfadoxine-pyrimethamine group was 100.63°F (range 96.8-103.8°F). Six patients were afebrile at day 0; 4 in the Chloroquine group and 2 in the Sulfadoxine-pyrimethamine group. All of them had a history of fever within the previous 24 hours.

The comparison of Fever Clearance Time (FCT) of both Chloroquine and Sulfadoxine-pyrimethamine arm was given in the Table 1 below.

<table>
<thead>
<tr>
<th>Parameters (in hours)</th>
<th>All patients (N=93*)</th>
<th>Chloroquine arm</th>
<th>Sulfadoxine-pyrimethamine arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>29.9</td>
<td>28.8</td>
<td>31</td>
</tr>
<tr>
<td>Median</td>
<td>24.0</td>
<td>24.0</td>
<td>24</td>
</tr>
<tr>
<td>Range</td>
<td>24-72</td>
<td>24-72</td>
<td>24-72</td>
</tr>
</tbody>
</table>

The difference of mean FCT of chloroquine and sulfadoxine-pyrimethamine group was not statistically significant (p value = 0.451832)

Table No 1: FEVER CLEARANCE TIME (FCT)

*Seven patients (5 in the chloroquine arm and 2 in the sulfadoxine-pyrimethamine arm), afebrile on the diagnosis, have been excluded for this analysis.

On Day 0, the mean parasite count of Chloroquine group was 10409.6 per µL (range 1040-95840 µL) and that of Sulfadoxine-pyrimethamine group was 9984.04 per µL (range 1040-72000 µL).

The comparison of Parasite Clearance Time (PCT) of both Chloroquine and Sulfadoxine-pyrimethamine arm was given in Table 2 below.

<table>
<thead>
<tr>
<th>Parameters (in hours)</th>
<th>All patients (N=94*)</th>
<th>Chloroquine arm</th>
<th>Sulfadoxine-pyrimethamine arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>72</td>
<td>82.7</td>
<td>61.3</td>
</tr>
<tr>
<td>Median</td>
<td>72</td>
<td>72</td>
<td>48</td>
</tr>
<tr>
<td>Range</td>
<td>48-168</td>
<td>48-168</td>
<td>48-168</td>
</tr>
<tr>
<td>Standard deviation</td>
<td>+ 35.195</td>
<td>+ 40.287</td>
<td>+ 25.423</td>
</tr>
</tbody>
</table>

The difference of mean PCT of chloroquine and sulfadoxine-pyrimethamine group was statistically significant (p value = 0.002648)

Table No 2: PARASITE CLEARANCE TIME (PCT)

*Six patients (3 in each of the chloroquine and sulfadoxine-pyrimethamine arm), lost during the follow up period, have been excluded for this analysis.
The comparison of treatment response in both Chloroquine and Sulfadoxine-pyrimethamine arm was given in Table 3 and pie chart below.

<table>
<thead>
<tr>
<th>Treatment Response</th>
<th>Chloroquine arm (N=50)</th>
<th>Sulfadoxine-pyrimethamine arm (N=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adequate Clinical and Parasitological Response (ACPR)</td>
<td>30 patients (60%)</td>
<td>46 patients (92%)</td>
</tr>
<tr>
<td>Late Treatment Failure (LTF)</td>
<td>15 patients (30%) (of which 9 patients had actually Late Clinical Failure and 6 had Late Parasitological Failure)</td>
<td>1 patient (2%) (actually Late Parasitological Failure)</td>
</tr>
<tr>
<td>Lost during follow up</td>
<td>5 patients (10%)</td>
<td>3 patients (6%)</td>
</tr>
</tbody>
</table>

Table 3: TREATMENT RESPONSE

This difference of LTF was significant (p value < 0.05).

**DISCUSSION:**

Chloroquine resistance status: In our study, it was observed that in the chloroquine group out of 50 patients, 30 (60%) showed Adequate Clinical and Parasitological Response (ACPR), 15 (30%) had Late Treatment Failure (LTF) and remaining 5 (10%) were lost during the follow up period.

Similar studies with Chloroquine conducted in different parts of the world showed varied results. Those are described below:

Kulkarni et al ⁴ (2000) reported 62.5% LTF cases in Mumbai. Ghosh et al ⁵ in Madras showed 5 resistance cases out of 6 samples and in Jabalpur district, Madhya Pradesh 12 (85.7%) resistance cases out of 14 samples. T Das Khatri ⁶ in 1991 reported 24% ACPR (out of 98 cases), 54% R I, 4% R II and 9% R III in Rajasthan. In West Bengal, Pandeya et al ² (1991) showed three R III foci - two in Jalpaiguri and one in Purulia districts. The studies showed a parasite clearance of 40 per cent and 32 per cent within seventh day in Purulia and Jalpaiguri districts respectively. Biswas S ³ (2005) reported 30% ACR, 54% LFT & 16% ETF in chloroquine treated cases from School of Tropical medicine, Kolkata. Recently, a study has been carried out from School of Tropical Medicine, Kolkata by Maji A. & Guha S. K. et al ⁷ (unpublished data) on status of antimalarial drug resistance of Plasmodium falciparum malaria in Uttar Latabari BPHC, Kalchini block & Dhumpara PHC, Nagrakata block in the district of Jalpaiguri in 2007-08. In Kalchini Block, the treatment failure rate of Chloroquine was 59 % (ETF 11.3% & LTF 47.7% cases) and the ACPR was 41%. In Dhumpara,
Nagrakata Block, the treatment failure rate of Chloroquine was 73% (ETF 14.6% & LTF 58.4% cases) and ACPR rate was 27%. In Pakistan, Khan et al in 2004 reported up to 16 - 62% chloroquine resistant Plasmodium falciparum cases. Ridwanur Rahman et al reported 56% ETF cases from Bangladesh in 1996-97. Maguire et al (2002) in Central Java, Indonesia reported 36 (47%) treatment failures. Checchi et al in Harper, south-west Liberia reported chloroquine failure rate of 84.0% (95% CI 70.9-92.8%). Moses et al in Kampala, Uganda showed 54% clinical failure and 72% parasitological failure. Fever clearance at day 3 was 85%.

Mahapatra et al in Changlang and Lohit districts of Arunachal Pradesh recorded 23.8% ETF, 14.3% LCF, 10.7% LPF and 51.2% ACPR. Schwobel et al in Lao PDR showed 44.8% early or late treatment failure. Checchi et al, in Sierra Leone, showed chloroquine failure proportions were ranging from 39.5% in Kabala to 78.8% in Kailahun. Early failures under CQ were frequent.

**Sulfadoxine-pyrimethamine resistance status:** In the present study, out of 50 patients in the Sulfadoxine-pyrimethamine (SP) group, 46 (92%) showed Adequate Clinical and Parasitological Response (ACPR) and only one (2%) had Late Treatment Failure (LTF) and 3 patients (6%) were lost during follow up period.

In Pakistan, Khan et al showed four to 25% of cases were resistant to sulfadoxine-pyrimethamine. A recent study in 2007-08 by Maqi A. & Guha S. K. et al (unpublished data) documented that in Kalchini Block, Jalpaiguri, the treatment failure rate of Sulfadoxine-Pyrimethamine was 19.5% (ETF 13% & LTF 6.5%) and the ACPR was 80.5%. In Nagrahakata Block of the same district, the treatment failure rate of Sulfadoxine-Pyrimethamine was 12% (ETF 2% & LTF 10%) and the ACPR was 88%. Biji et al (2000) reported 26% sulfadoxine-pyrimethamine resistant cases in Africa. Maguire et al (2002) in Central Java, Indonesia reported 22% treatment failures to SP. Almost similar results were observed in a study of SP resistance from Tanzania by Mugittu et al. They had documented 50.9% ACPR at Day 28 and 17.1% & 24.1% of clinical and parasitological failure respectively after 28 days of follow up. In Malawi, Plowe et al (2004) documented treatment failure rate of 20% in SP treated group. Checchi et al in Harper, south-west Liberia reported SP failure rate of 51.5%. In Gambia, Bojang et al showed ETF was 10.68% and LTF was 10% in SP treated patients. In Gambia another study by Muller et al showed ETF & LTF in Sulfadoxine-pyrimethamine group were 17% & 14% respectively. In Uganda, Talisuna et al observed parasitological failure was 61%. Checchi et al in western Uganda reported 37% ETF & 15.2% ETF. Moses et al in Kampala, Uganda reported 11% clinical failure and 30% parasitological failure among SP treated group. Mahapatra et al in Changlang and Lohit districts of Arunachal Pradesh recorded 14.1% ETF, 12.6% LCF, 8.1% LPF and 65.2% ACPR. Schwobel et al in Lao PDR documented 17.9% early or late treatment failure. Checchi et al, in Sierra Leone, observed that the SP failure rate varied from 23.2% in Kabala to 46.1% in Kailahun.

From the above discussion it is evident that the Chloroquine failure rate in Ward no. 44 of Kolkata Municipality Corporation is high (30%) which is well above (>10%) the WHO recommended cut off threshold for drug policy change, Sulfadoxine-pyrimethamine can be used in place of chloroquine as the first line drug in uncomplicated P. falciparum cases either alone or in combination with Chloroquine. Chloroquine failure rate was very much high in Jabalpur (85.7%) and in Harper, Liberia (84%) reported by Ghosh et al and Checchi et al respectively. Although the Sulfadoxine-pyrimethamine failure rate in other countries was very high but in our study in Kolkata
it was only 2%. Whether these high failure rates was due to recrudescence (i.e. true failure/resistance) or reinfection can only be confirmed by genetic study (PCR or DNA fingerprinting). Only 4 studies (Pandeya et al, De et al, Biswas et al and Maji & Guha S K et al) were done in West Bengal. Again our study gives an idea about the resistance pattern of central Kolkata only. To know the resistance pattern of whole of Kolkata similar studies should be carried out in other parts of the city viz. southern, north-eastern fringe and northern parts. It’s also important to carry out such studies in other malaria endemic districts of West Bengal (e.g. Jalpaiguri, Paschim Midnapur, Bankura and Purulia) for better understanding of the antimalarial drug sensitivity pattern in the state. It will be useful to establish few sentinel sites in malaria endemic districts of West Bengal to monitor the therapeutic efficacy of different anti-malarial drugs.

REFERENCES:


23. Manson’s Tropical Diseases, 22 nd & 21st edition, Table 73.14, p 1263.


AUTHORS:

1. Ayan Basu
2. Santanu Saha
3. Biswanath Sharma Sarkar
4. Somnath Mukherjee
5. Subhasish Kamal Guha
6. Dyuti Basu

PARTICULARS OF CONTRIBUTORS:

1. RMO Cum Clinical Tutor, Department of Tropical Medicine, School of Tropical Medicine, Kolkata.
2. Assistant Professor, Department of General Medicine, BSMCH, Bankura.
3. Associate Professor, Department of General Medicine, BSMCH, Bankura.
4. Senior Resident, Department of General Medicine, RG Kar Medical College, Kolkata.

5. Professor, Department of Tropical Medicine, School of Tropical Medicine, Kolkata.
6. Post Graduate Trainee, Department of Gynaecology & Obstetrics, Calcutta Medical College, Kolkata.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Ayan Basu,
46/27A, Becharam Chatterjee Road,
Behala, Kolkata – 700034,
West Bengal.
Email – ayanbasustm@gmail.com

Date of Submission: 27/12/2013.
Date of Peer Review: 28/12/2013.
Date of Acceptance: 01/01/2014.
Date of Publishing: 08/01/2014.